Introduction and Context
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has emerged as a global health crisis. Affecting approximately 30% of adults in the United States, it is the leading cause of chronic liver disease worldwide. Because MASLD is intrinsically linked to obesity, type 2 diabetes, and cardiovascular disease, the majority of patients are first encountered not by specialists, but by clinicians in primary care, endocrinology, and cardiology.
In 2021, the American Gastroenterological Association (AGA) released the first Clinical Care Pathway to help non-specialists navigate the complexities of liver screening. However, the field has moved at a rapid pace. Since that publication, we have seen a fundamental shift in nomenclature to reduce stigma and increase diagnostic precision, as well as the landmark FDA approval of the first medication specifically indicated for the more advanced stage of the disease, known as metabolic dysfunction-associated steatohepatitis (MASH). The updated 2026 Pathway, authored by Kanwal et al., provides a streamlined, evidence-based framework to identify those at highest risk for liver-related complications and cardiovascular events.
New Guideline Highlights
The core philosophy of the updated pathway is the transition from simple diagnosis to proactive risk stratification. The primary goal is no longer just to identify who has ‘fatty liver,’ but to identify who has significant liver fibrosis (scarring), as fibrosis is the most potent predictor of mortality and liver-related outcomes. Key highlights include:
- Universal Screening in High-Risk Groups: Clinicians are urged to screen patients with type 2 diabetes, obesity (especially with metabolic complications), or those with incidental findings of hepatic steatosis.
- Emphasis on Non-Invasive Testing (NIT): The pathway prioritizes simple blood-based calculations and specialized ultrasound techniques over invasive liver biopsies.
- Multidisciplinary Care: A call for collaborative management between primary care, endocrinology, and hepatology.
Updated Recommendations and Key Changes
The most significant change in the 2026 update is the integration of the new nomenclature and the inclusion of specific pharmacological management for MASH. Below is a summary of the key shifts from previous iterations:
| Feature | 2021 Original Pathway | 2026 Updated Pathway |
|---|---|---|
| Terminology | NAFLD / NASH | MASLD / MASH |
| First-Line Test | FIB-4 Index recommended | FIB-4 Index mandatory for risk stratification |
| Secondary Testing | VCTE (FibroScan) or ELF test | Refined cut-offs for VCTE and ELF; focus on ‘Grey Zone’ management |
| Pharmacotherapy | Focus on Vitamin E and Pioglitazone | Inclusion of Resmetirom (THR-β agonist) and GLP-1 RAs |
| Framework | Clinical guidance only | Added Implementation Framework for healthcare systems |
Topic-by-Topic Recommendations
1. Screening and Initial Assessment
The pathway identifies three primary ‘high-risk’ groups who should undergo systematic screening for MASLD, even if liver enzymes (ALT/AST) are normal:
- Patients with Type 2 Diabetes Mellitus (T2DM).
- Patients with two or more metabolic risk factors (hypertension, dyslipidemia, obesity).
- Patients with incidental liver fat noted on imaging (ultrasound, CT, MRI).
2. Risk Stratification via FIB-4
The Fibrosis-4 (FIB-4) index is the recommended first-line tool. It is a simple calculation using age, AST, ALT, and platelet count. The pathway categorizes patients into three risk tiers based on FIB-4 scores:
- Low Risk (FIB-4 < 1.3): These patients have a low probability of advanced fibrosis. They should be managed in primary care with a focus on lifestyle modification and metabolic risk factor control. FIB-4 should be repeated every 2–3 years.
- Intermediate Risk (FIB-4 1.3 – 2.67): Often referred to as the ‘grey zone,’ these patients require a second-line non-invasive test (NIT) to clarify their risk.
- High Risk (FIB-4 > 2.67): These patients have a high probability of advanced fibrosis (F3 or F4) and should be referred directly to a hepatologist.
3. Second-Line Testing (The ‘Grey Zone’)
For those in the intermediate-risk category, the pathway recommends either Vibration-Controlled Transient Elastography (VCTE), commonly known as FibroScan, or the Enhanced Liver Fibrosis (ELF) blood test.
- If VCTE Liver Stiffness Measurement (LSM) is < 8.0 kPa, the patient is low risk.
- If VCTE LSM is 8.0 – 12.0 kPa, the patient is intermediate risk and requires specialist consultation.
- If VCTE LSM is > 12.0 kPa, the patient is high risk for advanced fibrosis or cirrhosis.
4. Management and Treatment Strategies
The treatment approach is stratified by the stage of the disease. For all patients, lifestyle interventions (Mediterranean diet, 7–10% weight loss, and exercise) remain the cornerstone. However, the update adds specific medical guidance:
- Metabolic Control: Use of GLP-1 receptor agonists (e.g., semaglutide) and SGLT2 inhibitors is highly encouraged for patients with MASLD and T2DM or obesity, as these agents improve metabolic health and may reduce liver fat.
- MASH-Specific Therapy: For patients with biopsy-confirmed MASH and moderate-to-advanced fibrosis (F2–F3), the pathway now includes Resmetirom. As the first FDA-approved THR-β agonist, it has shown the ability to resolve MASH and improve fibrosis.
- Cardiovascular Health: Since cardiovascular disease is the leading cause of death in MASLD patients, aggressive management of LDL-cholesterol (statins) and blood pressure is mandatory.
Expert Commentary and Insights
The expert panel emphasizes that the nomenclature change from ‘Non-Alcoholic’ to ‘Metabolic Dysfunction-Associated’ is more than just semantics. It centers the disease on its underlying cause: metabolic health. Dr. Fasiha Kanwal, the lead author, notes that ‘the previous terminology was exclusionary and potentially stigmatizing. By focusing on metabolic dysfunction, we align liver care with the management of diabetes and heart disease.’
A point of ongoing discussion among the experts is the ‘intermediate risk’ group. The panel acknowledges that access to VCTE or ELF testing can be a barrier in rural or underserved areas. To address this, the updated pathway includes an implementation framework that suggests health systems integrate FIB-4 calculations directly into Electronic Health Record (EHR) systems to provide automatic ‘reflex’ testing or alerts for clinicians.
Practical Implications: A Patient Vignette
Case Study: Robert
Robert is a 52-year-old male with a BMI of 32 and Type 2 Diabetes. His routine labs show a normal ALT of 28 U/L. Under previous standards, his liver might have been ignored. However, using the new Pathway, his primary care physician calculates a FIB-4 score. Despite normal enzymes, his FIB-4 is 1.8 (Intermediate Risk). The physician orders a VCTE (FibroScan), which reveals a stiffness of 9.5 kPa. Robert is referred to a hepatology-led multidisciplinary clinic. He is started on a GLP-1 receptor agonist for his diabetes and weight, and because his liver stiffness suggests F2 fibrosis, he is evaluated for MASH-specific therapy. This proactive approach prevents Robert from progressing to silent cirrhosis.
References
- Kanwal F, Bril F, Wai-Sun Wong V, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. Gastroenterology. 2026;170(3):1120-1145.
- Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus on new nomenclature for steatotic liver disease. Hepatology. 2023;78(6):1966-1986.
- Harrison SA, Bedossa P, Guyot FG, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. New England Journal of Medicine. 2024;390(6):497-509.
- Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. Endocrine Practice. 2022;28(5):528-562.